|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
La Jolla Pharmaceutical Company
| | | Phone: | (858) 452-6600 | Fax: | (858) 626-2851 | Year Established: | 1989 | Ticker: | LJPC | Exchange: | OTCBB | Main Contact: | George F. Tidmarsh, M.D., Ph.D., President & CEO | | Other Contacts: | James M. Rolke, CSO Jeffrey J. Jensen, VP, Global Clinical Operations James A. Wilkie, VP, New Enterprise Development Jennifer A. Carver, MBA, COO Dennis M. Mulroy, CFO Lakhmir S. Chawla, MD, CMO
| | Company Description | La Jolla Pharmaceutical is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company has historically focused on the development and testing of Riquent® (abetimus sodium), as a treatment for patients with lupus. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions. | |
|
|
|
|
|